Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines

Jean D. Sipe, Merrill Benson, Joel N. Buxbaum, Shu Ichi Ikeda, Giampaolo Merlini, Maria J M Saraiva, Per Westermark

Research output: Contribution to journalArticle

210 Citations (Scopus)

Abstract

The Nomenclature Committee of the International Society of Amyloidosis (ISA) met during the XVth Symposium of the Society, 3 July–7 July 2016, Uppsala, Sweden, to assess and formulate recommendations for nomenclature for amyloid fibril proteins and the clinical classification of the amyloidoses. An amyloid fibril must exhibit affinity for Congo red and with green, yellow or orange birefringence when the Congo red-stained deposits are viewed with polarized light. While congophilia and birefringence remain the gold standard for demonstration of amyloid deposits, new staining and imaging techniques are proving useful. To be included in the nomenclature list, in addition to congophilia and birefringence, the chemical identity of the protein must be unambiguously characterized by protein sequence analysis when possible. In general, it is insufficient to identify a mutation in the gene of a candidate amyloid protein without confirming the variant changes in the amyloid fibril protein. Each distinct form of amyloidosis is uniquely characterized by the chemical identity of the amyloid fibril protein that deposits in the extracellular spaces of tissues and organs and gives rise to the disease syndrome. The fibril proteins are designated as protein A followed by a suffix that is an abbreviation of the parent or precursor protein name. To date, there are 36 known extracellular fibril proteins in humans, 2 of which are iatrogenic in nature and 9 of which have also been identified in animals. Two newly recognized fibril proteins, AApoCII derived from apolipoprotein CII and AApoCIII derived from apolipoprotein CIII, have been added. AApoCII amyloidosis and AApoCIII amyloidosis are hereditary systemic amyloidoses. Intracellular protein inclusions displaying some of the properties of amyloid, “intracellular amyloid” have been reported. Two proteins which were previously characterized as intracellular inclusions, tau and α-synuclein, are now recognized to form extracellular deposits upon cell death and thus have been included in Table 1 as ATau and AαSyn.

Original languageEnglish (US)
Pages (from-to)209-213
Number of pages5
JournalAmyloid
Volume23
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Amyloidogenic Proteins
Amyloidosis
Amyloid
Terminology
Guidelines
Birefringence
Familial Amyloidosis
Congo Red
Proteins
Synucleins
Apolipoprotein C-II
Apolipoprotein C-III
Protein Precursors
Protein Sequence Analysis
Amyloid Plaques
Staphylococcal Protein A
Extracellular Space
Sweden
Names
Cell Death

Keywords

  • Amyloid fibril
  • amyloid protein
  • amyloidosis
  • inclusion body
  • nomenclature

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Amyloid fibril proteins and amyloidosis : chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. / Sipe, Jean D.; Benson, Merrill; Buxbaum, Joel N.; Ikeda, Shu Ichi; Merlini, Giampaolo; Saraiva, Maria J M; Westermark, Per.

In: Amyloid, Vol. 23, No. 4, 01.10.2016, p. 209-213.

Research output: Contribution to journalArticle

Sipe, Jean D. ; Benson, Merrill ; Buxbaum, Joel N. ; Ikeda, Shu Ichi ; Merlini, Giampaolo ; Saraiva, Maria J M ; Westermark, Per. / Amyloid fibril proteins and amyloidosis : chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. In: Amyloid. 2016 ; Vol. 23, No. 4. pp. 209-213.
@article{afaf0b78b32a4d95a1d0f9dde6480a5d,
title = "Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines",
abstract = "The Nomenclature Committee of the International Society of Amyloidosis (ISA) met during the XVth Symposium of the Society, 3 July–7 July 2016, Uppsala, Sweden, to assess and formulate recommendations for nomenclature for amyloid fibril proteins and the clinical classification of the amyloidoses. An amyloid fibril must exhibit affinity for Congo red and with green, yellow or orange birefringence when the Congo red-stained deposits are viewed with polarized light. While congophilia and birefringence remain the gold standard for demonstration of amyloid deposits, new staining and imaging techniques are proving useful. To be included in the nomenclature list, in addition to congophilia and birefringence, the chemical identity of the protein must be unambiguously characterized by protein sequence analysis when possible. In general, it is insufficient to identify a mutation in the gene of a candidate amyloid protein without confirming the variant changes in the amyloid fibril protein. Each distinct form of amyloidosis is uniquely characterized by the chemical identity of the amyloid fibril protein that deposits in the extracellular spaces of tissues and organs and gives rise to the disease syndrome. The fibril proteins are designated as protein A followed by a suffix that is an abbreviation of the parent or precursor protein name. To date, there are 36 known extracellular fibril proteins in humans, 2 of which are iatrogenic in nature and 9 of which have also been identified in animals. Two newly recognized fibril proteins, AApoCII derived from apolipoprotein CII and AApoCIII derived from apolipoprotein CIII, have been added. AApoCII amyloidosis and AApoCIII amyloidosis are hereditary systemic amyloidoses. Intracellular protein inclusions displaying some of the properties of amyloid, “intracellular amyloid” have been reported. Two proteins which were previously characterized as intracellular inclusions, tau and α-synuclein, are now recognized to form extracellular deposits upon cell death and thus have been included in Table 1 as ATau and AαSyn.",
keywords = "Amyloid fibril, amyloid protein, amyloidosis, inclusion body, nomenclature",
author = "Sipe, {Jean D.} and Merrill Benson and Buxbaum, {Joel N.} and Ikeda, {Shu Ichi} and Giampaolo Merlini and Saraiva, {Maria J M} and Per Westermark",
year = "2016",
month = "10",
day = "1",
doi = "10.1080/13506129.2016.1257986",
language = "English (US)",
volume = "23",
pages = "209--213",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Amyloid fibril proteins and amyloidosis

T2 - chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines

AU - Sipe, Jean D.

AU - Benson, Merrill

AU - Buxbaum, Joel N.

AU - Ikeda, Shu Ichi

AU - Merlini, Giampaolo

AU - Saraiva, Maria J M

AU - Westermark, Per

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The Nomenclature Committee of the International Society of Amyloidosis (ISA) met during the XVth Symposium of the Society, 3 July–7 July 2016, Uppsala, Sweden, to assess and formulate recommendations for nomenclature for amyloid fibril proteins and the clinical classification of the amyloidoses. An amyloid fibril must exhibit affinity for Congo red and with green, yellow or orange birefringence when the Congo red-stained deposits are viewed with polarized light. While congophilia and birefringence remain the gold standard for demonstration of amyloid deposits, new staining and imaging techniques are proving useful. To be included in the nomenclature list, in addition to congophilia and birefringence, the chemical identity of the protein must be unambiguously characterized by protein sequence analysis when possible. In general, it is insufficient to identify a mutation in the gene of a candidate amyloid protein without confirming the variant changes in the amyloid fibril protein. Each distinct form of amyloidosis is uniquely characterized by the chemical identity of the amyloid fibril protein that deposits in the extracellular spaces of tissues and organs and gives rise to the disease syndrome. The fibril proteins are designated as protein A followed by a suffix that is an abbreviation of the parent or precursor protein name. To date, there are 36 known extracellular fibril proteins in humans, 2 of which are iatrogenic in nature and 9 of which have also been identified in animals. Two newly recognized fibril proteins, AApoCII derived from apolipoprotein CII and AApoCIII derived from apolipoprotein CIII, have been added. AApoCII amyloidosis and AApoCIII amyloidosis are hereditary systemic amyloidoses. Intracellular protein inclusions displaying some of the properties of amyloid, “intracellular amyloid” have been reported. Two proteins which were previously characterized as intracellular inclusions, tau and α-synuclein, are now recognized to form extracellular deposits upon cell death and thus have been included in Table 1 as ATau and AαSyn.

AB - The Nomenclature Committee of the International Society of Amyloidosis (ISA) met during the XVth Symposium of the Society, 3 July–7 July 2016, Uppsala, Sweden, to assess and formulate recommendations for nomenclature for amyloid fibril proteins and the clinical classification of the amyloidoses. An amyloid fibril must exhibit affinity for Congo red and with green, yellow or orange birefringence when the Congo red-stained deposits are viewed with polarized light. While congophilia and birefringence remain the gold standard for demonstration of amyloid deposits, new staining and imaging techniques are proving useful. To be included in the nomenclature list, in addition to congophilia and birefringence, the chemical identity of the protein must be unambiguously characterized by protein sequence analysis when possible. In general, it is insufficient to identify a mutation in the gene of a candidate amyloid protein without confirming the variant changes in the amyloid fibril protein. Each distinct form of amyloidosis is uniquely characterized by the chemical identity of the amyloid fibril protein that deposits in the extracellular spaces of tissues and organs and gives rise to the disease syndrome. The fibril proteins are designated as protein A followed by a suffix that is an abbreviation of the parent or precursor protein name. To date, there are 36 known extracellular fibril proteins in humans, 2 of which are iatrogenic in nature and 9 of which have also been identified in animals. Two newly recognized fibril proteins, AApoCII derived from apolipoprotein CII and AApoCIII derived from apolipoprotein CIII, have been added. AApoCII amyloidosis and AApoCIII amyloidosis are hereditary systemic amyloidoses. Intracellular protein inclusions displaying some of the properties of amyloid, “intracellular amyloid” have been reported. Two proteins which were previously characterized as intracellular inclusions, tau and α-synuclein, are now recognized to form extracellular deposits upon cell death and thus have been included in Table 1 as ATau and AαSyn.

KW - Amyloid fibril

KW - amyloid protein

KW - amyloidosis

KW - inclusion body

KW - nomenclature

UR - http://www.scopus.com/inward/record.url?scp=84997221695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997221695&partnerID=8YFLogxK

U2 - 10.1080/13506129.2016.1257986

DO - 10.1080/13506129.2016.1257986

M3 - Article

C2 - 27884064

AN - SCOPUS:84997221695

VL - 23

SP - 209

EP - 213

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

IS - 4

ER -